Five of the most commonly ignored signs of acute leukaemia



BLOOD cancer symptoms are important to recognise with it being the fifth most common cancer in the UK and the third deadliest form of cancer. Acute leukaemia is one of the most common types of blood cancer, but what are the most commonly ignored signs?

Related Links:

In this study, we first tested the role of Peg-Dox in the killing of myeloid cell lines and of primary myeloid leukemia cells. Then, a Peg-Dox-based protocol was used to treat patients with myeloid neoplasms. The results showed that the Peg-Dox and Peg-Dox-based protocols had a similar killing ability in myeloid cell lines and in primary myeloid leukemia cells compared to that of conventional doxorubicin. The complete remission rate was 87.5% and 100% for patients with refractory/relapsed acute myeloid leukemia and myelodysplastic syndrome with excess blasts, respectively, after treatment with Peg-Dox. All patients develop…

Source: Anti-Cancer DrugsCategory: Cancer & Oncology Tags: Clinical Reports Source Type: research

ConclusionsOur study demonstrated that CXCR4 expression in AML was an independent prognostic predictor for disease survival that could be rapidly and easily determined by flow cytometry at disease presentation.

Source: Cancer MedicineCategory: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

In conclusion, the use of NGS panels in MN improves genetic characterization of the disease compared with conventional methods, thus demonstrating its potential clinical utility in routine clinical testing. This approach leads to better-adjusted treatments for each patient.

Source: CancersCategory: Cancer & Oncology Authors: Tags: Article Source Type: research

rer S
In this review article, we present recent updates on the hematological tumor microenvironment following the 3rd Scientific Workshop on the Haematological Tumour Microenvironment and its Therapeutic Targeting organized by the European School of Hematology, which took place at the Francis Crick Institute in London in February 2019. This review article is focused on recent scientific advances highlighted in the invited presentations at the meeting, which encompass the normal and malignant niches supporting hematopoietic stem cells and their progeny. Therefore, for the sake of focus it does not discuss …

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

Obesity correlates with hematological malignances including leukemias, but risk of specific leukemia subtypes like Acute Promyelocytic Leukemia and underlying molecular mechanisms are poorly understood. We explored multiple datasets for correlation between leukemia, Body Mass Index and molecular features. In a population-based study (n=5.2 million), we correlated Body Mass Index with promyelocytic, other acute myeloid, lymphoid or other leukemias. In cross-sectional studies, we tested body mass index deviation in promyelocytic leukemia trial cohorts from what expected based on national surveys. We interro…

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

In conclusion, these recent studies strongly support CD123 as an important therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and other hematological malignancies will have to be evaluated by in the ongoing clinical studies.

Source: CancersCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

Conclusion.Progression of CLL, AML, and NHL was associated with higher health care costs over a 12‐month period. Delaying cancer progression resulted in a substantial cost reduction in patients with all three cancer types.Implications for Practice.Data on the rates and incremental health care costs of disease progression in patients with hematologic malignancies are lacking. This study estimated the incremental costs of disease progression in patients diagnosed with chronic lymphocytic leukemia, acute myeloid leukemia, and non‐Hodgkin’s lymphoma and compared health care costs in patients with and without evidence of di…

Source: The OncologistCategory: Cancer & Oncology Authors: Tags: Leukemias, Lymphoma, Hematologic Malignancies, Health Outcomes and Economics of Cancer Care Source Type: research

B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 18% of the afflicted patients during the first 5 years after diagnosis. Molecular heterogeneities of pediatric B-ALL play important roles as determinants of the therapy response. Therefore, many of these molecular abnormalities have an established prognostic value in the disease. The present review discusses the omics-based revel…

Source: Oncology ReviewsCategory: Cancer & Oncology Source Type: research

Authors: Maggi M, Scotti C
Cancer treatment has greatly improved over the last 50 years, but it remains challenging in several cases. Useful therapeutic targets are normally unique peculiarities of cancer cells that distinguish them from normal cells and that can be tackled with appropriate drugs. It is now known that cell metabolism is rewired during tumorigenesis and metastasis as a consequence of oncogene activation and oncosuppressors inactivation, leading to a new cellular homeostasis typically directed towards anabolism. Because of these modifications, cells can become strongly or absolutely dep…

Basophils are white blood cells that play an important role in the human immune system. These cells physiologically increase in number in immune response to certain allergies, chronic inflammation and parasitic infections. But are also a significant indicator for the presence of certain malignancies such as chronic myeloproliferative neoplasms and acute myeloid leukemia.
In the current manuscript we present a statistically significant correlation between increasing basophilia in primary myelofibrosis (PMF) and the risk for the subsequent development of an acute myeloid leukemia.
We retrospectively identified in the fil…


Source link